FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916149712> ?p ?o ?g. }

• W2916149712 endingPage "525" @default.
• W2916149712 startingPage "512" @default.
• W2916149712 abstract "We investigated the effects of glial cell line-derived neurotrophic factor (GDNF) in Parkinson’s disease, using intermittent intraputamenal convection-enhanced delivery via a skull-mounted transcutaneous port as a novel administration paradigm to potentially afford putamen-wide therapeutic delivery. This was a single-centre, randomized, double-blind, placebo-controlled trial. Patients were 35–75 years old, had motor symptoms for 5 or more years, and presented with moderate disease severity in the OFF state [Hoehn and Yahr stage 2–3 and Unified Parkinson’s Disease Rating Scale motor score (part III) (UPDRS-III) between 25 and 45] and motor fluctuations. Drug delivery devices were implanted and putamenal volume coverage was required to exceed a predefined threshold at a test infusion prior to randomization. Six pilot stage patients (randomization 2:1) and 35 primary stage patients (randomization 1:1) received bilateral intraputamenal infusions of GDNF (120 µg per putamen) or placebo every 4 weeks for 40 weeks. Efficacy analyses were based on the intention-to-treat principle and included all patients randomized. The primary outcome was the percentage change from baseline to Week 40 in the OFF state (UPDRS-III). The primary analysis was limited to primary stage patients, while further analyses included all patients from both study stages. The mean OFF state UPDRS motor score decreased by 17.3 ± 17.6% in the active group and 11.8 ± 15.8% in the placebo group (least squares mean difference: −4.9%, 95% CI: −16.9, 7.1, P = 0.41). Secondary endpoints did not show significant differences between the groups either. A post hoc analysis found nine (43%) patients in the active group but no placebo patients with a large clinically important motor improvement (≥10 points) in the OFF state (P = 0.0008). 18F-DOPA PET imaging demonstrated a significantly increased uptake throughout the putamen only in the active group, ranging from 25% (left anterior putamen; P = 0.0009) to 100% (both posterior putamina; P < 0.0001). GDNF appeared to be well tolerated and safe, and no drug-related serious adverse events were reported. The study did not meet its primary endpoint. 18F-DOPA imaging, however, suggested that intermittent convection-enhanced delivery of GDNF produced a putamen-wide tissue engagement effect, overcoming prior delivery limitations. Potential reasons for not proving clinical benefit at 40 weeks are discussed." @default.
• W2916149712 created "2019-03-02" @default.
• W2916149712 creator A5001902655 @default.
• W2916149712 creator A5002111430 @default.
• W2916149712 creator A5006087787 @default.
• W2916149712 creator A5009789130 @default.
• W2916149712 creator A5013719565 @default.
• W2916149712 creator A5016398070 @default.
• W2916149712 creator A5019140248 @default.
• W2916149712 creator A5027643529 @default.
• W2916149712 creator A5032888002 @default.
• W2916149712 creator A5034663097 @default.
• W2916149712 creator A5038942434 @default.
• W2916149712 creator A5044809041 @default.
• W2916149712 creator A5047075962 @default.
• W2916149712 creator A5052581318 @default.
• W2916149712 creator A5056032715 @default.
• W2916149712 creator A5057497497 @default.
• W2916149712 creator A5060244960 @default.
• W2916149712 creator A5066908279 @default.
• W2916149712 creator A5067560744 @default.
• W2916149712 creator A5067881698 @default.
• W2916149712 creator A5072732777 @default.
• W2916149712 creator A5072924990 @default.
• W2916149712 creator A5074026658 @default.
• W2916149712 creator A5078132016 @default.
• W2916149712 creator A5078458714 @default.
• W2916149712 creator A5079516438 @default.
• W2916149712 creator A5079751864 @default.
• W2916149712 creator A5079888730 @default.
• W2916149712 creator A5086392680 @default.
• W2916149712 creator A5090573082 @default.
• W2916149712 date "2019-02-26" @default.
• W2916149712 modified "2023-10-17" @default.
• W2916149712 title "Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease" @default.
• W2916149712 cites W1866157615 @default.
• W2916149712 cites W1971208141 @default.
• W2916149712 cites W1971258758 @default.
• W2916149712 cites W1974726724 @default.
• W2916149712 cites W1976788622 @default.
• W2916149712 cites W1978793506 @default.
• W2916149712 cites W1991208841 @default.
• W2916149712 cites W1996001296 @default.
• W2916149712 cites W1997769836 @default.
• W2916149712 cites W1997887984 @default.
• W2916149712 cites W1999128801 @default.
• W2916149712 cites W2004261781 @default.
• W2916149712 cites W2006376003 @default.
• W2916149712 cites W2013110094 @default.
• W2916149712 cites W2014744592 @default.
• W2916149712 cites W2019695510 @default.
• W2916149712 cites W2030549077 @default.
• W2916149712 cites W2031584008 @default.
• W2916149712 cites W2032554568 @default.
• W2916149712 cites W2032620009 @default.
• W2916149712 cites W2040344246 @default.
• W2916149712 cites W2054810445 @default.
• W2916149712 cites W2057454582 @default.
• W2916149712 cites W2063723084 @default.
• W2916149712 cites W2065259720 @default.
• W2916149712 cites W2068728747 @default.
• W2916149712 cites W2082868177 @default.
• W2916149712 cites W2082977534 @default.
• W2916149712 cites W2094061170 @default.
• W2916149712 cites W2103623402 @default.
• W2916149712 cites W2103899142 @default.
• W2916149712 cites W2107160883 @default.
• W2916149712 cites W2116581820 @default.
• W2916149712 cites W2122085123 @default.
• W2916149712 cites W2128294582 @default.
• W2916149712 cites W2129167248 @default.
• W2916149712 cites W2134886133 @default.
• W2916149712 cites W2135907949 @default.
• W2916149712 cites W2138462240 @default.
• W2916149712 cites W2149731696 @default.
• W2916149712 cites W2159329523 @default.
• W2916149712 cites W2165526364 @default.
• W2916149712 cites W2178835613 @default.
• W2916149712 cites W2574348854 @default.
• W2916149712 cites W2611934788 @default.
• W2916149712 cites W2769041674 @default.
• W2916149712 cites W2804936366 @default.
• W2916149712 cites W4241671361 @default.
• W2916149712 doi "https://doi.org/10.1093/brain/awz023" @default.
• W2916149712 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6391602" @default.
• W2916149712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30808022" @default.
• W2916149712 hasPublicationYear "2019" @default.
• W2916149712 type Work @default.
• W2916149712 sameAs 2916149712 @default.
• W2916149712 citedByCount "185" @default.
• W2916149712 countsByYear W29161497122019 @default.
• W2916149712 countsByYear W29161497122020 @default.
• W2916149712 countsByYear W29161497122021 @default.
• W2916149712 countsByYear W29161497122022 @default.
• W2916149712 countsByYear W29161497122023 @default.
• W2916149712 crossrefType "journal-article" @default.
• W2916149712 hasAuthorship W2916149712A5001902655 @default.
• W2916149712 hasAuthorship W2916149712A5002111430 @default.

• next